Yazar "Mehtap, Özgür" için listeleme
-
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
Merih Urlu, Selin; Cengiz Seval, Güldane; Erdoğan Yücel, Elçin; Mehtap, Özgür; Yenihayat, Emel Merve; Polat, Merve Gökçen; Malkan, Ümit Yavuz; Karakuş, Volkan (American Society of Hematology, 2023)Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ... -
CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: A multicenter study
Demirci, Ufuk; Kırkızlar, Hakkı Onur; Ümit, Elif Gülsüm; Gürsoy, Vildan; Pınar, İbrahim Ethem; Özkalemkaş, Fahir; Güven, Zeynep Tuğba; Kaynar, Leylagül; Keklik Karadağ, Fatma; Saydam, Güray; Ekinci, Ömer; Merter, Mustafa; Aras, Merih Reis; Albayrak, Murat; Karaman Gülsaran, Sedanur; Baş, Volkan; Balık Aydın, Berrin; Beköz, Hüseyin Saffet; Can, Ferda; Dilek, İmdat; Mehtap, Özgür; Öztürk, Erman; Çobanoğlu Şimşek, Bengü; Yıldırım, Murat; Aylı, Meltem; Ataş, Ünal; Salim, Ozan; Ayer, Mesut; Birtaş Ateşoğlu, Elif; Akay, Olga Meltem; Kurt Yüksel, Meltem; Paydaş, Semra; Korkmaz, Selçuk; Öz Puyan, Fulya; Demir, Ahmet Muzaffer (Springer Science and Business Media Deutschland GmbH, 2022)Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality ... -
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey
Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Beşışık, Sevgi; Yenerel, Mustafa Nuri; Çelik, Serhat; Kaynar, Leylagül; Yücel, Orhan Kemal; Deveci, Burak; Sönmez, Mehmet; Mehtap, Özgür; Beköz, Hüseyin Saffet; Sunu, Cenk; Salim, Ozan; Ulaş, Turgay; Kartı, Sami; Altuntaş, Fevzi; Ferhanoğlu, Burhan; Tuğlular, Tülin Fırat (Springer, 2023)Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had ... -
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
Yiğit Kaya, Süreyya; Mutlu, Yaşa Gül; Malkan, Ümit Yavuz; Mehtap, Özgür; Keklik Karadağ, Fatma; Korkmaz, Gülten; Elverdi, Tuğrul; Saydam, Güray; Özet, Gülsüm; Ar, Muhlis Cem; Melek, Elif; Maral, Senem; Kaynar, Leylagül; Sevindik, Ömür Gökmen (2024)Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. ...